Proscia Inc. — Cyborg Score 8/10

Strong
Diagnostic Laboratories

Strategic Profile

Proscia is biopharma's partner of choice to put pathology AI into practice. The company leverages an open-architecture platform that integrates AI solutions across drug discovery, clinical trials, companion diagnostics, and diagnostics labs, positioning it at the intersection of precision medicine and digital transformation in pathology.

Cyborg Score Rationale

Proscia more than doubled its growth in 2024, validated by customer adoption among top-tier pharma and diagnostic labs. The company has FDA 510(k) clearance and CE-IVDR certification for its diagnostic software, and was recognized as one of the Next Big Things in Tech 2024 by Fast Company and named to the Fierce 15 list of innovative biotech companies in 2025.

Top Insights

  • Proscia more than doubled its growth in 2024, signaling strong market traction
  • 14 of the top 20 pharmaceutical companies rely on Proscia's solutions, representing highly sticky enterprise concentration
  • Proscia released 12+ platform updates in 2024, including the industry's first multi-AI workflows on Concentriq AP, and secured FDA 510(k) clearance for Concentriq AP-Dx
  • Proscia's customer experience practice has reduced average time to go live by over 30%, with 100% of its customers interviewed by KLAS willing to repurchase

Named Competitors

  • PathAI — AI-powered pathology platform for cancer diagnosis using machine learning
  • Ibex — AI solutions for pathology and diagnostics
  • Philips Digital Pathology — Digital pathology solutions and imaging systems
  • 4D Path — Digital pathology image analysis
  • Techcyte — Digital pathology and computational analysis

Recent Developments

  • (May 2026) Proscia honored alongside IQVIA, Medidata, and Thermo Fisher Scientific
  • (January 2025) Proscia more than doubled growth in 2024, cemented leadership position with life sciences organizations and diagnostic laboratories increasingly deploying Concentriq
  • (February 2024) FDA 510(k) clearance granted for Concentriq AP-Dx, enabling Proscia to expand marketing efforts to diagnostic laboratories facing staffing pressures

Open the full interactive Proscia Inc. report

Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.

Open report →